Sales: $2.8 billion
Key Personnel: Andrew Witty, chief executive officer; Roger Connor, president, global manufacturing and supply; Simon Dingemans, chief financial officer; Nick Hirons, senior vice president, global ethics and compliance; David Redfern, chief strategy officer; Emma Walmsley, chief executive officer, GSK Consumer Healthcare.
Major Products: Oral care—Sensodyne, Polident/Corega, Parodontax, Biotene and Aquafresh.
New Products: Aquafresh Multi-Action Whitening, Sensodyne Repair and Protect Whitening, and Sensodyne Complete toothpastes; Sensodyne mouthwash.
Comments: Corporate sales rose 1% last year. GlaxoSmithKline is best known for its pharmaceutical business, but the company maintains it is the No. 3 player in the global oral care market (behind Colgate and P&G). Last year, Sensodyne led the way, with double-digit sales gains. Now, the toothpaste is closing in on annual sales of £1 billion. In fact, thanks to the successful launch of Sensodyne Complete, the brand is the leading toothpaste in Japan.
Earlier this year, GSK earned a patent for a formula designed to protect teeth against dental erosion and/or toothwear. It is comprised of applying to teeth an oral care composition comprising sodium fluoride, potassium nitrate, and a triple polymer system consisting of xanthan gum, carboxymethylcellulose and copovidone.
In Q1 2016, consumer health care sales rose 26% to more than £1.7 billion due primarily to favorable exchange rates. Oral care sales played a role in the increase, but GSK noted that Aquafresh sales declined due to competitive pressure. That decline was more than offset by gains made by Sensodyne, gum health and denture products.